Showing results (121-130 of 160) with videos related to
Sort By:
Pageof 16
British Journal of Clinical Pharmacology|June 27, 2014
Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetesMatthew M Riggs, Leo J Seman, Alexander Staab, et al.BMJ Open|March 8, 2013
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitusJorge Luiz Gross, James Rogers, Daniel Polhamus, et al.British Journal of Clinical Pharmacology|July 21, 2010
Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladderYasuhiro Tsuda, Shinji Tatami, Norio Yamamura, et al.Biochemical Pharmacology|July 27, 2018
Can toxicokinetics of (synthetic) cannabinoids in pigs after pulmonary administration be upscaled to humans by allometric techniques?Nadine Schaefer, Jan-Georg Wojtyniak, Ann-Katrin Kroell, et al.Viruses|October 27, 2022
Model-Based Analysis of SARS-CoV-2 Infections, Hospitalization and Outcome in Germany, the Federal States and DistrictsChristiane Dings, Katharina Martha Götz, Katharina Och, et al.Infectious Disease Modelling|August 26, 2024
Effect of vaccinations and school restrictions on the spread of COVID-19 in different age groups in GermanyChristiane Dings, Dominik Selzer, Nicola Luigi Bragazzi, et al.British Journal of Clinical Pharmacology|November 21, 2024
Toxicokinetic modelling of the synthetic cannabinoid 5F-MDMB-P7AICA and its main metabolite in pigs following pulmonary administrationAdrian A Doerr, Christiane Dings, Omar Zaher, et al.Archives of Toxicology|December 4, 2024
Does a carboxamide moiety alter the toxicokinetics of synthetic cannabinoids? A study after pulmonary and intravenous administration of cumyl-5F-P7AICA to pigsNadja Walle, Christiane Dings, Omar Zaher, et al.Thrombosis and Haemostasis|February 8, 2013
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal diseaseDmytro Khadzhynov, Frank Wagner, Stephan Formella, et al.Journal of Hepatology|February 10, 2015
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approachSandra M Ehrlich, Johanna Liebl, Maximilian A Ardelt, et al.Pageof 16